This project seeks to apply biomarkers for mucopolysaccharidoses (MPS) to the development of an innovative newborn screening (NBS) system for this group of lysosomal storages diseases. Background: MPS are caused by excessive accumulation of glycosaminoglycans (GAGs) from a deficiency of enzyme activity catalyzing their degradation. There are 11 known enzyme deficiencies that give rise to seven distinct forms of MPS with an overall incidence of approximately 1 out of 25,000 live births that indicates approximately 200 newborn patients per year in the Unites States. The accumulation of undegraded storage material in lysosomes causes different clinical syndromes. Generally, the clinical conditions progress if untreated, leading to irreversible developmental delay, systemic skeletal deformities and/or early death. These MPS disorders are potentially treatable with enzyme replacement therapy or hematopoietic stem cell transplantation. The quality of life for MPS patients treated with these therapies dramatically improves when treatment begins at an early stage. Early detection (through NBS) will allow maximum therapeutic benefit of these and other novel therapies. However, conventional laboratory screening methods for MPS are designed to measure urinary total GAGs (heparan sulfate: HS, keratan sulfate: KS, dermatan sulfate: DS, chondroitin sulfate: CS) and cannot be applied to NBS blood samples. We describe a two-tiered approach to NBS for MPS by using high performance liquid chromatography tandem mass spectrometry (LC/MS/MS). The first-tier screen will identify an """"""""at increased risk"""""""" population for all types of MPS based on simultaneous assay of specific GAG markers (DS, HS and KS) using dried blood spots. The subsequent second-tier individual enzyme assays provide definitive diagnosis. Challenges: Since cost-effectiveness is a key for NBS, a highly efficient, sensitive, specific and inexpensive screening method is required. The cost of screening each type of MPS would be high and prohibitive as the incidence rates range from about 1:100,000 births to less than 1:2,000,000 births. However, screening for MPS as a group with a combined incidence of about 1:25,000 births would be comparable to other genetic disorders currently targeted by existing screening programs. The new LC/MS/MS method enables the simultaneous detection of a group of MPS and is promising for NBS. Perspective in proposed research plan: We will establish a NBS method for MPS with simultaneous determination of three major GAGs (DS, HS and KS) as biomarkers. In addition to the NBS application we will measure GAGs as biomarkers for assessing disease severity and monitoring the effects of evolving therapies over a long clinical course.
Mucopolysaccharidoses (MPS) are a group of inborn errors of metabolism caused by deficiency of lysosomal enzyme activities, leading to accumulation of glycosaminoglycans (a chain of sugars) such as dermatan sulfate, heparan sulfate, chondroitin sulfate, and keratan sulfate in multiple organs causing systemic bone deformities, enlarged abdominal organs, hearing loss, valvular heart disease, mental retardation and early death. Our research proposal addresses development of a novel newborn screening method for MPS that enables early diagnosis and potential treatment, preventing serious irreversible damage and leading to a better quality of life. We propose to perform a newborn screening pilot study for MPS to evaluate our innovative method.
|Alméciga-Díaz, Carlos J; Montaño, Adriana M; Barrera, Luis A et al. (2018) Tailoring the AAV2 capsid vector for bone-targeting. Pediatr Res 84:545-551|
|Peracha, Hira; Sawamoto, Kazuki; Averill, Lauren et al. (2018) Molecular genetics and metabolism, special edition: Diagnosis, diagnosis and prognosis of Mucopolysaccharidosis IVA. Mol Genet Metab 125:18-37|
|Sawamoto, Kazuki; Chen, Hui-Hsuan; Alméciga-Díaz, Carlos J et al. (2018) Gene therapy for Mucopolysaccharidoses. Mol Genet Metab 123:59-68|
|Khan, Shaukat A; Mason, Robert W; Giugliani, Roberto et al. (2018) Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis. Mol Genet Metab 125:44-52|
|Khan, Shaukat A; Peracha, Hira; Ballhausen, Diana et al. (2017) Epidemiology of mucopolysaccharidoses. Mol Genet Metab 121:227-240|
|Kubaski, Francyne; Brusius-Facchin, Ana Carolina; Mason, Robert W et al. (2017) Elevation of glycosaminoglycans in the amniotic fluid of a fetus with mucopolysaccharidosis VII. Prenat Diagn 37:435-439|
|Khan, Shaukat; Alméciga-Díaz, Carlos J; Sawamoto, Kazuki et al. (2017) Mucopolysaccharidosis IVA and glycosaminoglycans. Mol Genet Metab 120:78-95|
|Kubaski, Francyne; Suzuki, Yasuyuki; Orii, Kenji et al. (2017) Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses. Mol Genet Metab 120:247-254|
|Stapleton, Molly; Kubaski, Francyne; Mason, Robert W et al. (2017) Presentation and Treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome). Expert Opin Orphan Drugs 5:295-307|
|Kubaski, Francyne; Mason, Robert W; Nakatomi, Akiko et al. (2017) Newborn screening for mucopolysaccharidoses: a pilot study of measurement of glycosaminoglycans by tandem mass spectrometry. J Inherit Metab Dis 40:151-158|
Showing the most recent 10 out of 30 publications